secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagonist Therapeutics, Inc (PTGX)
CIK:        0001377121
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001104659-24-058036
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagonist Q1 net income $207.3M on $255M Takeda revenue; cash runway through Q4 2027
--------------------------------------------------------------------------------

- Net income of $207.3M ($3.26 diluted EPS) vs net loss of $33.7M in Q1 2023; revenue $255M from Takeda rusfertide license.
- Cash, equivalents & marketable securities $322.6M at March 31, 2024; extended runway through Q4 2027 including $300M upfront from Takeda.
- Phase 3 ICONIC LEAD and ICONIC TOTAL trials of JNJ-2113 in psoriasis completed enrollment; Phase 3 ICONIC ADVANCE studies ongoing.
- Expect to nominate oral IL-17 antagonist development candidate by end of 2024.
- Rusfertide VERIFY study top-line data expected by Q1 2025; potential deal value with Takeda up to $630M plus profit share/royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1377121/000110465924058036/0001104659-24-058036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1377121/000110465924058036/tm2413671d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-058036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer